The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) (93) and the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) (94) have demonstrated a reduction in the risk of MACE, thereby supporting the cardiovascular benefits associated with glucagon-like peptide 1 receptor (GLP-1R) agonist therapy. This evidence concerns the gene GLP1R and diabetes mellitus.